Pharma Industrial India - Professional magazine for pharma industry suppliers and lab technology

NEWS ABOUT >

Biotechnology

Clean Rooms

Clinical Trials

Consultants

Digitalization

Drug Discovery & Development

Engineering

Global Pharma

Industrial talks

Ingredients

Lab Equipment

Logistics & Distribution

Manufacturing

Market

Outsourcing

Packaging

Quality / GMP

Regulation

Safety

Last edition

All magazines
Subscribe to our magazine

News about "imsidolimab "

Vanda Pharma's Imsidolimab Gets EU Orphan Designation for Psoriasis

Vanda Pharmaceuticals’ imsidolimab receives European Union (EU) orphan designation for Generalised Pustular Psoriasis (GPP), marking the first such designation for a GPP treatment in the EU.

Imsidolimab | 26/08/2026 | By News Bureau

Vanda Pharmaceuticals's Imsidolimab BLA Accepted by U.S. Food and Drug Administration for Rare Skin Disease GPP

Vanda’s imsidolimab moves closer to approval as the FDA accepts its BLA for generalised pustular psoriasis, a rare and life-threatening inflammatory skin disorder.

Imsidolimab | 02/03/2026 | By News Bureau | 283

Vanda and Anaptys to Develop and Commercialize Imsidolimab

GPP is a rare skin disorder often caused by mutations in the IL36RN gene that codes for a regulatory protein that balances the activity of the proinflammatory IL-36 family of cytokines.

Imsidolimab | 04/02/2025 | By Aishwarya | 606

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members